Interleukin-2 toxicity: mechanisms and management

  • Johanna W. Baars


Interleukin-2 (IL-2) is a glycoprotein produced by activated T cells which is able to induce a response in 15–30% of the patients with metastatic renal cell cancer or melanoma [1–5].


Lymphokine Activate Killer Lymphokine Activate Killer Cell Metastatic Renal Cell Cancer Vascular Leak Syndrome Septic Shock Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rosenberg SA, Lotze MJ, Yang JC, et al. Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474–85.PubMedCrossRefGoogle Scholar
  2. 2.
    West WH, Tauer KW, Yanelli JR, et al. Constant-infusion recombinant Interleukin-2 in adoptive immunotherapy of advanced cancer. N Eng J Med 1987; 316: 898–905.CrossRefGoogle Scholar
  3. 3.
    Eberlein TJ, Schoof DD, Jung SE, et al. A new regimen of interleukin-2 and lymphokine activated killer cells. Efficacy without significant toxicity. Arch Int Med 1988; 148: 2571–6.CrossRefGoogle Scholar
  4. 4.
    Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7: 477–85.PubMedGoogle Scholar
  5. 5.
    Fisher RJ, Coltman CA, Doroshow JH. Metastatic renal cell cancer treated with interleukin-2 and lymphokine activated killer cells. Ann Int Med 1988; 108: 518–23.PubMedGoogle Scholar
  6. 6.
    Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicty and management guidelines. J Clin Oncol 1989; 7: 486–98.PubMedGoogle Scholar
  7. 7.
    Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694–704.PubMedGoogle Scholar
  8. 8.
    Atzpodien J, Körfer A, Franks CR, et al. Home therapy with recombinant interleukin-2 and interferon a 2b in advanced human malignancies. Lancet 1990; 335: 1509–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low dose Intravenous Interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6: 409–24.PubMedGoogle Scholar
  10. 10.
    Thompson JA, Lee DJ, Lindgren CG, et al. Influence of schedule of Interleukin-2 administration on therapy with Interleukin-2 and lymphokine activated killer cells. Cancer Res 1989; 49: 235–40.PubMedGoogle Scholar
  11. 11.
    Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 1986; 137: 1735–42.PubMedGoogle Scholar
  12. 12.
    Mier JW, Vachino G, Van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8: 426–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Gemlo BT, Palladino MA, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant Interleukin 2 and lymphokine-activated-killer cells. Cancer Res 1988; 48: 5864–67.PubMedGoogle Scholar
  14. 14.
    Kasahara T, Hooks JJ, Daugherty SF, Oppenheim JJ. Interleukin-2 mediated immune interferon (IFN-7) production by human T cells and T cell subsets. J Immunol 1983; 130: 1784–89.PubMedGoogle Scholar
  15. 15.
    Nedwin GE, Svedersky LP, Bringman TS, et al. Effect of interleukin-2, interferon-g and mitogens on the production of tumor necrosis factors a and ß. J Immunol 1985; 135: 2492–7.PubMedGoogle Scholar
  16. 16.
    Marshall ME, Cibull MH, Peason T, et al. Human recombinant Interleukin-2 provokes infiltration of lymphocytes into myocardium and liver in rabbits. J Biol Response Mod 1990; 9: 279–87.PubMedGoogle Scholar
  17. 17.
    Anderson TD, Hayes TJ. Toxicity of human recombinant Interleukin-2 in rats. Pathologic changes are characterized by marked lymphocytic and eosinophilic proliferation and multisystem involvement. Lab Invest 1989; 60: 331–46.PubMedGoogle Scholar
  18. 18.
    Thijs LG, Hack CE, Strack van Schijndel RJM, et al. Activation of the complement system during immunotherapy with Interleukin-2. Relation to the development of side effects. J Immunol 1990; 144: 2419–24.PubMedGoogle Scholar
  19. 19.
    Prozanski W, Vadas P. Phospholipase A2 -a mediator between proximal and distal effectors of inflammation. Immunol Today 1991; 12: 143–6.Google Scholar
  20. 20.
    Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant Interleukin-2 in Mice. J Natl Cancer Inst 1988; 80: 177–88.PubMedCrossRefGoogle Scholar
  21. 21.
    Fairman RP, Glauser FL, Merchant RE, et al. Increase of rat pulmonary microvascular permeability to albumin by recombinant interleukin-2. Cancer Res 1987; 47: 3528–32.PubMedGoogle Scholar
  22. 22.
    Anderson TD, Hayes TJ, Gately MK, et al. Toxicity of human recombinant Interleukin-2 in the mouse is mediated by Interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. Lab Invest 1988; 59: 598–612.PubMedGoogle Scholar
  23. 23.
    Aronson FR, Libby P, Brandon EP, et al. IL-2 rapidly induces natural killer adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol 1988; 141: 158–63.PubMedGoogle Scholar
  24. 24.
    Damle NK, Doyle LV. IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial Monolayers. Implication for vascular leak syndrome. J Immunol 1989; 142: 2660.PubMedGoogle Scholar
  25. 25.
    Ferro TJ, Johnson A, Everitt J, Malik AB. IL-2 induces pulmonary edema and vasoconstruction independent of circulating lymphocytes. J Immunol 1989; 142: 1916–21.PubMedGoogle Scholar
  26. 26.
    Beckhard DE, Fairman RP, Hinshaw DB, et al. In vivo Interleukin-2 activated sheep lung lymph lymphocytes increase ovine vascular endothelial permeability by non-lytic mechanisms. Eur J Cancer 1990; 26: 1074–8.CrossRefGoogle Scholar
  27. 27.
    Cotran RS, Pober JS, Gimbrone MA Jr, et al. Endothelial activation during interleukin-2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 1988; 140: 1883–8.PubMedGoogle Scholar
  28. 28.
    Stolpen AH, Guinan EC, Fiers W, et al. Recombinant tumor necrosis factor and immune interferon act simply and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 1986; 123: 16–24.PubMedGoogle Scholar
  29. 29.
    Puri RK, Rosenberg SA. Combined effects of interferon Ƴ and interleukin 2 on the induction of a vascular leak syndrome in mice. Cancer Immunol Immunother 1989; 28: 267–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Mier JW, Brandon EP, Libby P, et al. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury: possible role of induced cytokines in limiting capillary leak during IL-2 therapy. J Immunol 1989; 143: 2407–14.PubMedGoogle Scholar
  31. 31.
    Puri RK, Travis WD, Rosenberg SA. Decrease in Interleukin-2 induced vascular leakage in the lungs of mice by administration of recombinant Interleukin la in vivo. Cancer Res 1989; 49: 969–76.PubMedGoogle Scholar
  32. 32.
    Baars JW, Hack CE, Wagstaff J, et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br J Cancer 1992;65:96–101.PubMedCrossRefGoogle Scholar
  33. 33.
    Vachino G, Gelfand JA, Atkins MB, et al. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2 activated lymphocytes. Blood 1991; 78: 2505–13.PubMedGoogle Scholar
  34. 34.
    Welbourn R, Goldman G, Kobzik L, et al. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg 1990; 212: 728–33.PubMedCrossRefGoogle Scholar
  35. 35.
    Slotman GJ, Burchard KW, Williams JJ, et al. Interaction of prostaglandins, activated complement and granulocytes in clinical sepsis and hypotension. Surgery 1986; 90: 744–54.Google Scholar
  36. 36.
    Lee RE, Lotze MT, Skibber JM, et al. Cardiorespiratory effects of immunotherapy with Interleukin-2. J Clin Oncol 1989; 7:7–20.PubMedGoogle Scholar
  37. 37.
    Ognibene FP, Rosenberg SA, Lotze M, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1988; 94: 750–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Davis SD, Berkmen YM, Wang JCL. Interleukin-2 therapy for advanced renal cell carcinoma: Radiographic evaluation of response and complications. Radiology 1990; 177: 127–31.PubMedGoogle Scholar
  39. 39.
    Gaynor ER, Vitek L, Sticklin L, et al. The hemodynamic efects of treatment with Interleukin-2 and lymphokine activated killer cells. Ann Int Med 1988; 109: 953–8.PubMedGoogle Scholar
  40. 40.
    Nora R, Abrams JS, Tait NC, et al. Myocardial toxic effects during recombinant Interleukin-2 therapy. J Natl Cancer Inst 1989; 81: 59–63.PubMedCrossRefGoogle Scholar
  41. 41.
    Osanto S, Cluitmans FRM, Franks CR, et al. Myocardial injury after interleukin-2 therapy. Lancet 1988; 11: 48–9(Letter to the editor).CrossRefGoogle Scholar
  42. 42.
    Sobotka PA, McMannis J, Fisher RI, et al. Effect of Interleukin-2 or cardiac function in the isolated rat heart. J Clin Invest 1990; 86: 845–50.PubMedCrossRefGoogle Scholar
  43. 43.
    Favalli L, Lanza E, Rozza A, et al. Evaluation of the cardiovascular toxic effect of recombinant Lnterleukin-2 in Rats. Anticancer Res 1990; 10: 1693–8.PubMedGoogle Scholar
  44. 44.
    Gulick T, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1986; 86: 6753–7.CrossRefGoogle Scholar
  45. 45.
    Hanis RL, Musker DM, Bloom K, et al. Manifestations of sepsis. Arch Int Med 1987; 147: 1895–906.CrossRefGoogle Scholar
  46. 46.
    Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991; 338: 732–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Nuyens JH, Huybregts CCM, Eerenberg-Belmer AJM, et al. Quantification of plasma factor Xlla-Cl inhibitor and Kallikrein-Cl inhibitor complexes in sepsis. Blood 1988; 72: 1841–8.Google Scholar
  48. 48.
    Hack CE, Wagstaff J, Strack van Schijndel RJM, et al. Studies on the contact system of coagulation during therapy with high dose of recombinant IL-2: Implications for septic shock. Thromb Haemost 1991; 65: 497–504.PubMedGoogle Scholar
  49. 49.
    Jacobs HS, Craddock PR, Hammerschimdt DE, Moldow CF. Complement induced granulocyte aggregation. N Engl J Med 1980; 302: 789–94.CrossRefGoogle Scholar
  50. 50.
    Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to Interferon g in combination with tumor necrosis factor, Interleukin-1 or Endotoxin. J Natl Cancer Inst 1990; 82: 772–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Nathan CF, Stuehr DJ. Does endothelium-derived nitric oxide have a role in cytokine-induced hypotension? J Natl Cancer Inst 1990; 82: 726–8.(Editorial)PubMedCrossRefGoogle Scholar
  52. 52.
    Kilbourn RG, Jubran A, Gross SS, et al. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Bioch Biophys Res Commun 1990; 172: 1132–8.CrossRefGoogle Scholar
  53. 53.
    Hibbs JB, Westenfelder C, Taintor R, et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992; 89: 867–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Harms BA, Pahl AC, Pohlman, et al. Effects of interleukin-2 on pulmonary and systemic transvascular fluid filtration. Surgery 1989; 106: 339–46.PubMedGoogle Scholar
  55. 55.
    Glauser FL, de Blois GG, Bechard E, et al. Cardiopulmonary effects of recombinant interleukin-2 infusion in sheep. J Appl Physiol 1988; 64: 1030–7.PubMedGoogle Scholar
  56. 56.
    Butler LD, Mohler KM, Layman NK, et al. Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic intervention. Immunopharm Immunotox 1989; 11: 445–87.CrossRefGoogle Scholar
  57. 57.
    Klausner JM, Paterson IS, Morel NML, et al. Role of thomboxane in Interleukin 2 induced lung injury in sheep. Cancer Res 1989; 49: 3542–9.PubMedGoogle Scholar
  58. 58.
    Textor SC, Margolin K, Blayney D, et al. Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. Am J Med 1987; 83:1055–61.PubMedCrossRefGoogle Scholar
  59. 59.
    Webb DE, Austin HA III, Belldegrun A, et al. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988; 30: 141–5.PubMedGoogle Scholar
  60. 60.
    Kozeny GA, Nicolas JD, Creekmore S, et al. Effects of Interleukin-2 immunotherapy on renal function. J Clin Oncol 1988; 6: 1170–6.PubMedGoogle Scholar
  61. 61.
    Shalmi CL, Dutcher JP, Feinfeld DA, et al. Acute renal dysfunction during interleukin-2 treatment. Suggestion of an intrinsic renal lesion. J Clin Oncol 1990; 8: 1839–46.PubMedGoogle Scholar
  62. 62.
    Belldegrun A, Webb DE, Austin HA III, et al. Renal toxicity of Interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 1989; 141:499–503.PubMedGoogle Scholar
  63. 63.
    Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of interleukin-2. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst. 1988; 80: 1451–61.PubMedCrossRefGoogle Scholar
  64. 64.
    Schwartzentruber D, Lotze MT, Rosenberg SA. Colonic perforation. An unusual compli-cation of therapy with high-dose Interleukin-2. Cancer 1988; 62: 2350–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Birchfield GR, Ward JH, Redman BG, et al. Interleukin-2 immunotherapy for malignant melanoma. West J Med 1990; 152: 714–6.PubMedGoogle Scholar
  66. 66.
    Fisher B, Keenan AM, Garra BS, et al. Interleukin-2 induces profound reversible cholestasis: A detailed analysis in treated cancer patients. J Clin Oncol 1989; 7: 1852–62.PubMedGoogle Scholar
  67. 67.
    Jablons DM, Mule JM, Mclntosh J, et al. Interleukin 6/Interferon-β2 as a circulating hormone: Induction by cytokine administration in humans. J Immunol 1989; 142: 1542–7.PubMedGoogle Scholar
  68. 68.
    Imura H, Fukata J, Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clinical Endocrinol 1991; 35: 107–15.CrossRefGoogle Scholar
  69. 69.
    Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Eng J Med 1988; 318: 1557–63.CrossRefGoogle Scholar
  70. 70.
    Van Liessum PA, de Mulder PHM, Mattijssen EJM, et al. Hypothyroidism and goitre during interleukin-2 therapy without LAK cells. Lancet 1989; ii: 224(Letter).CrossRefGoogle Scholar
  71. 71.
    Burman P, Tötterman TH, Oberg K, Karlsson FA. Thyroid auto-immunity in patients on long term therapy with leucocyte-derived Interferon. J Clin Endocrinol Metab 1986; 63: 1086–90.PubMedCrossRefGoogle Scholar
  72. 72.
    Fentiman IS, Balkwill FR, Thomas BS, et al. An autoimmune actiology for hypothyroidism following Interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988; 24: 1299–303.PubMedCrossRefGoogle Scholar
  73. 73.
    Weetman AP, Volkman DJ, Burman KD, et al. The in vitro regulation of human thyrocyte HLA-DR antigen expression. J Clin Endocrin Metab 1985; 61: 817–24.CrossRefGoogle Scholar
  74. 74.
    Martin A, Huber GK, Davies TF. Induction of human thyroid cell ICAM-1 (CD-54) antigen expression and ICAM-1 mediated lymphocyte binding. Endocrinology 1990; 127: 651–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Kung AWC, Jones BM, Lai CL. Effects of interferon-y therapy on thyroid function, T-lymphocyte subpopulations and induction of autoantibodies. J Endocrinol Metab 1990; 71: 1230–4.CrossRefGoogle Scholar
  76. 76.
    Bogner U, Single B, Schleusener H. Interferon-y protects human thyroid epithelial cells against cell mediated cytotoxicity. Immunobiol 1988; 176: 423–31.CrossRefGoogle Scholar
  77. 77.
    Hoekman K, Von Blomberg-van de Flier BME, Wagstaff J, et al. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541–2.PubMedCrossRefGoogle Scholar
  78. 78.
    Schaafsma MR, Falkenburg JHF, Landegent JE, et al. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophage-colony-stimulating factor and interleukin-6 during intravenous administration of high dose interleukin-2 in cancer patients. Blood 1991; 78: 1981–87.PubMedGoogle Scholar
  79. 79.
    Michie HR, Eberlein TJ, Spriggs DR, et al. Interleukin-2 initiates metabolic responses associated with critical illness in humans. Ann Surg 1988; 208: 493–501.PubMedCrossRefGoogle Scholar
  80. 80.
    Atkins MB, Gould JA, Allegretta M, et al. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986; 4: 1380–91.PubMedGoogle Scholar
  81. 81.
    Denicoff KD, Durkin TM, Lotze MT, et al. The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 1989; 69: 402–20.PubMedCrossRefGoogle Scholar
  82. 82.
    Vetto JT, Papa MZ, Lotze MT, et al. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 1987; 5: 496–503.PubMedGoogle Scholar
  83. 83.
    Van der Molen LA, Smith JWII, Longo DL, et al. Adrenal insufficiency and Interleukin-2 therapy. Ann Intern Med 1989; 111: 185(Letter).Google Scholar
  84. 84.
    Wilson DE, Birchfield GR, Hejazi JS, et al. Hypocholesterolemia in patients treated with recombinant Interleukin-2. Appearance of remnant-like lipoprotein. J Clin Oncol 1989; 7: 1573–8.PubMedGoogle Scholar
  85. 85.
    Gaspari AA, Lotze MT, Rosenberg SA, et al. Dermatologic changes associated with Interleukin-2 administration. JAMA 1987; 258: 1624–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Weinstein A, Brijak D, Mittelman A, et al. Erythema nodosum in a patients with renal cell carcinoma treated with interleukin-2 and lymphokine-activated killer cells. JAMA 1987; 258: 3120–1.PubMedCrossRefGoogle Scholar
  87. 87.
    Mier JW, Aronson FR, Numer of PR, et al. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Path Immunopathol Res 1988; 7: 459–76.CrossRefGoogle Scholar
  88. 88.
    Ramseur WL, Richards FII, Duggan DB. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy. Cancer 1989; 63: 2005–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Staunton MR, Sailly MC, Le Boit PE, Aronson FR. Life threatening bullous skin eruptions during Interleukin-2 therapy. J Natl Cancer Inst 1991; 83: 56–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Lee RE, Gaspari AA, Lotze MT, et al. Interleukin-2 and psoriasis. Arch Dermatol 1988; 124: 1811–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Denicoff KD, Rubinow DR, Papa MZ. The neuropsychiatric effects of treatment with Interleukin-2 and lymphokine-activated killer cells. Ann Int Med 1987; 107: 293–300.PubMedGoogle Scholar
  92. 92.
    Ellison MD, Povlishock JT, Merchant RE. Blood-brain barried dysfunction in cats following recombinant Interleukin-2 infusion. Cancer Res 1987; 47: 5765–70.PubMedGoogle Scholar
  93. 93.
    Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol 1988; 15: 10–26.PubMedGoogle Scholar
  94. 94.
    Goey SH, Voerman HJ, Strack van Schijndel RJM, et al. Swelling of metastatic tumors with high-dose interleukin therapy. N Engl J Med 1988; 318: 643–4(Letter).PubMedCrossRefGoogle Scholar
  95. 95.
    Ettinghausen SE, Moore JG, White DE, et al. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant Interleukin-2 in cancer patients. Blood 1987; 69: 1654–60.PubMedGoogle Scholar
  96. 96.
    Tritarelli E, Rocca E, Testa U, et al. Adoptive immunotherapy with high dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6. Blood 1991; 77: 741–9.PubMedGoogle Scholar
  97. 97.
    Enokihara H, Furusawa S, Nakakubo H, et al. T cells from eosinophilic patients produce Interleukin-5 with Interleukin-2 stimulation. Blood 1989; 73: 1809–13.PubMedGoogle Scholar
  98. 98.
    Perez R, Padavic K, Krigel R, Weiner L. Antierythrocyte autoantibody formation after therapy with Interleukin-2 and Gamma-Interferon. Cancer 1991; 67: 2512–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Nawroth PP, Stern DM. Tumor necrosis factor/cachectin-induced modulation of endothelial cell hemostatic properties. Onkologie 1987; 10: 254–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Van der Poll T, Buller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Eng J Med 1990; 332: 1622–7.CrossRefGoogle Scholar
  101. 101.
    Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 165–1172.CrossRefGoogle Scholar
  102. 102.
    Richard V, Bernier M, Themelin L, et al. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r Met Hu IL-2 [alal25]). Ann Oncol 1991; 2: 67–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Kahalek MB, Le Roy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989; 110: 446–50.Google Scholar
  104. 104.
    Hooks JJ, Moutsopaulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Eng J Med 1979; 301: 5–8.CrossRefGoogle Scholar
  105. 105.
    Jones AL, Cropley I, O’Brien MER, et al. Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet 1992; 339: 181–2.PubMedCrossRefGoogle Scholar
  106. 106.
    Bock SN, Lee RE, Fisher B, et al. A prospective randomzied trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 1990; 8: 161–9.PubMedGoogle Scholar
  107. 107.
    Hardy JR, Moore J, Lorentzos A, et al. Infectious complications of interleukin-2 therapy. Cytokine 1990;2:311.PubMedCrossRefGoogle Scholar
  108. 108.
    Murphy PM, Lane HC, Gallin JL, et al. Marked disparity in incidence of bacterial infections in patients with the acquired immuno-deficiency syndrome receiving interleukin-2 or interferon-alpha. Ann Intern Med 1988; 108: 36–41.PubMedGoogle Scholar
  109. 109.
    Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients. Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988; 6: 1440–9.PubMedGoogle Scholar
  110. 110.
    Jabbons D, Bolton E, Mertin S, et al. Interleukin-2 based immunotherapy alters circulating neutrophils Fc receptor expression and chemotoxis. J Immunol 1990; 144: 3630–6.Google Scholar
  111. 111.
    Klempner MS, Noring R, Mier JW, et al. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Eng J Med 1990; 332: 959–66.CrossRefGoogle Scholar
  112. 112.
    Balkwill FR. Abnormal IL-2 production and IL-2 receptor expression in haematological malignancies. (Resp: understanding the role of cytokines in the process of malignancy) In: Balkwill FR, editor. Cytokines in cancer therapy. Oxford: Oxford University Press, 1989: 110–3 (resp. 238–9).Google Scholar
  113. 113.
    Mavligit GM, Zakiwiski A, Gutterman JU, et al. Splenic versus hepatic artery infusion of Interleukin-2 in patients with liver metastases. J Clin Oncol 1990; 8: 319–24.PubMedGoogle Scholar
  114. 114.
    Eggermont AMM, Goey SH, Wiggers TH, et al. Hepatic artery infusion with Interleukin-2 in patients with unresectable colorectal hepatic metastatic disease: A phase 1B Study. Nat Immun Cell Growth Regul 1990; 9: 73–4.Google Scholar
  115. 115.
    Steis RG, Urba WJ, Van der Molen LA, et al. Intraperitoneal lymphokine-activated killer cell and Interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 1990; 8: 1618–29.PubMedGoogle Scholar
  116. 116.
    Yasumoto K, Miyuzaki K, Nagaskima A, et al. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 47: 2184–7.PubMedGoogle Scholar
  117. 117.
    Eggermont AMM, Goey SH, Slingerland R, et al. Intrapleural administration of recombinant Interleukin-2 (IL-2) in patients with malignant pleural mesothelioma: A Phase II study. Nat Immun Cell Growth Regul 1990; 9: 74–5(abstract).Google Scholar
  118. 118.
    Blancher A, Roubinet F, Grancher AS, et al. Adoptive local immunotherapy of malignant gliomas. Nat Immun Cell Growth Regul 1990; 9: 72(abstract).Google Scholar
  119. 119.
    Merchant RE, Ellison MD, Young HF. Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of preclinical and clinical investigations. J Neuro Oncol 1990; 8: 173–88.CrossRefGoogle Scholar
  120. 120.
    Hulan E, Hulan H. Local continuous high dose Interleukin-2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 1989; 49: 5469–74.Google Scholar
  121. 121.
    Kolitz JE, Wong GY, Welte K, et al. Phase I trial of recombinant interleukin-2 and cyclophosphamide. Augmentation of cellular immunity and T-cell mitogenic response with long-term administration of r IL-2. J Biol Response Mod 1988; 7: 457–72.PubMedGoogle Scholar
  122. 122.
    Kirchner H, Körfer A, Evers P, et al. The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural Interleukin-2. Cancer 1991; 67: 1862–4.PubMedCrossRefGoogle Scholar
  123. 123.
    Mule JJ, Shu S, Schwarz SL, et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9.PubMedCrossRefGoogle Scholar
  124. 124.
    La Freniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 1985;45:3735–41.Google Scholar
  125. 125.
    Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10: 275–81.PubMedGoogle Scholar
  126. 126.
    Silagi S, Schaefer AE. Successful immunotherapy of mouse melanoma and sarcoma with recombinant Interleukin-2 and Cyclophosphamide. J Biol Response Mod 1986; 5: 411–22.PubMedGoogle Scholar
  127. 127.
    Papa MZ, Yang JC, Vetto JC, et al. Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 1988; 48: 122–9.PubMedGoogle Scholar
  128. 128.
    Lindeman A, Höffner K, Schmidt RE, et al. A phase II study of low dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 1989; 28: 275–81.CrossRefGoogle Scholar
  129. 129.
    Mier JW, Vachino G, Klempner M, et al. Inhibition of Interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chematoxis defect and differential suppression of Interleukin-2 associated side effects. Blood 1990; 76: 1933–40.PubMedGoogle Scholar
  130. 130.
    Fraker DL, Langstein HN, Norton JA. Passive immunization against tumor necrosis factor partially abrogates interleukin-2 toxicity. J Exp Med 1989; 170: 1015–20.PubMedCrossRefGoogle Scholar
  131. 131.
    Blay JY, Favrot MC, Negrier S, et al. Correlation between clinical response to Interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 1990; 50: 2371–4.PubMedGoogle Scholar
  132. 132.
    Schwartzberg L, Tauer K, Birch R, et al. Phase I study of sequential recombinant tumor necrosis factor (rTNF) and recombinant interleukin-2 (r-IL-2) in patients with advanced malignancy. Proc ASCO 1989; 8: 183(abstract).Google Scholar
  133. 133.
    Baars JW, de Boer JP, Wagstaff J, et al. Interleukin-2 induces activation and fibrinolysis: resemblance to changes seen during experimental endotoxaemia. BJ Haematol. 1992; 82:285–301.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • Johanna W. Baars

There are no affiliations available

Personalised recommendations